Company intelligence / Profile preview

Vision Pharma

Estero, Florida, United States

Ownership: Private
Employees: ~57
Development stage: Other

Overview

Vision Pharma has been operating for over 20 years. Its core innovation is a patented platform for combining carbonation with liquid formulations to enhance onset of action, absorption, taste, and stability, applied to APIs such as diphenhydramine, doxylamine, and dextromethorphan. The company has been granted three US patents for these combinations and is focused on niche generic products targeting allergy, sleep, pain, and nausea. Specific clinical results are not publicly reported.

Therapeutic areas: ImmunologyNeurologyInfectious DiseasesGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Strategic pharmaceutical organizations (domestic and international)

Beyond the preview

Go deeper on Vision Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vision Pharma.

Explore the full profile